Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer

Cancer

Volumn 107, Issue 5, 2006, Pages 908-915

  Stewart, Alexandra J ^a,b   Viswanathan, Akila N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Concomitant chemotherapy; High dose rate (HDR) brachytherapy; Low dose rate (LDR) brachytherapy; Stage III cervical cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; HEMOGLOBIN; VINCRISTINE;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOXIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA;

BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33747873560     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22054     Document Type: Review

References (60)

1. Lanciano RM, Martz K, Coia LR, Hanks GE. Tumor and treatment factors improving outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys. 1991;20:95-100.
2. Montana GS, Fowler WC, Varia MA, Walton LA, Mack Y, Shemanski L. Carcinoma of the cervix, stage III results of radiation therapy. Cancer. 1986;57:148-154.
3. Paley PJ, Goff BA, Minudri R, Greer BE, Tamimi HK, Koh WJ. The prognostic significance of radiation dose and residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma. Gynecol Oncol. 2000;76:373-379.
4. Eifel PJ, Thoms WW Jr, Smith TL, Morris M, Oswald MJ. The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 1994;28:113-118.
5. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix (Review). Cochrane Database Syst Rev. 2005;4:CD002225.
6. International Commission on Radiation Units and Measurements (ICRU), Dose and volume specifications for reporting intracavitary therapy in gynecology. Bethesda, MD: ICRU, 1985. ICRU Report no. 38.
7. Nag S, Orton C, Young D, et al. The American Brachytherapy Society Survey of brachytherapy practice for carcinoma of the cervix in the United States. Gyn Oncol. 1999;73:111-118.
8. Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. Int J Radiat Oncol Biol Phys. 2004;60:1144-1153.
9. Foroudi F, Bull CA, Gebski V. Radiation therapy for cervix carcinoma: Benefits of individualized dosimetry. Clin Oncol. 2002;14:43-49.
10. Mai J, Erickson B, Rownd J, et al. Comparison of four different dose specification methods for high dose rate intracavitary radiation for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2001;51:1131-1141.
11. Orton C. High dose rate brachytherapy may be radiobiologically superior to low dose rate due to slow repair of late responding normal tissue cells. Int J Radiat Oncol Biol Phys. 2001;49:183-189.
12. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32:1275-1288.
13. Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995;32:1301-1307.
14. Chen SW, Liang JA, Yang SN, et al. The adverse effect of treatment prolongation in cervical cancer by high dose rate intracavitary brachytherapy. Radiother Oncol. 2003;67:69-76.
15. Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high dose rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48:201-211.
16. Fyles AW, Pintilie M, Kirkbride P, et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis. Radiother Oncol. 1995;35:107-117.
17. Kapp DS, Fischer D, Gutierrez, et al. Pretreatment prognostic factors in carcinoma of the uterine cervix: A multivariate analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys. 1983;9:445-455.
18. Winter WE III, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94:495-501.
19. Lee SW, Suh CO, Chung EJ, et al. Dose optimization of fractionated external radiation and high dose rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:1338-1344.
20. Stitt JA, Fowler JF, Thomadsen BR, et al. High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Madison system: I. Clinical and radiobiological consideration. Int J Radiat Oncol Biol Phys. 1992;24:335-348.
21. Kama Y, Uematsu M, Nagata I, et al. Carcinoma of the uterine cervix: Twice versus once-weekly high dose rate brachytherapy. Radiology. 2001;219:207-212.
22. Chao KSC, Williamson JF, Grigsby PW, et al. Uterosacral space involvement in locally advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1998;40:397-403.
23. Petereit DG, Sarkaria JN, Potter DM, et al. High dose rate versus low dose rate brachytherapy in the treatment of cervical cancer: Analysis of tumor recurrence-the University of Wisconsin experience. Int J Radiat Oncol Biol Phys. 1999;45:1267-1274.
24. Kim WC, Kim GE, Suh CO, et al. High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix. Jpn J Clin Oncol. 2001;31:432-437.
25. Sarkaria JN, Petereit DG, Stitt JA, et al. A comparison of the efficacy and complication rates of low dose rate versus high dose rate brachytherapy in the treatment of uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 1994;30:75-82.
26. Kucera H, Potter R, Knocke TH, et al. High dose versus low dose rate brachytherapy in definitive radiotherapy of cervical cancer. Wien Klin Wochenschr. 2001;113:58-62.
27. Orton CG, Seyedsadr M, Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys. 1991;21:1425-1434.
28. Okkan S, Atkovar G, Sahinler I, et al. Results and complications of high dose rate and low dose rate brachytherapy in carcinoma of the cervix: Cerrahpasa experience. Radiother Oncol. 2003;67:97-105.
29. Hsu WL, Wu CJ, Jen YM, Yen SH, Lin KT, Ger LP, et al. Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: A nonrandomised comparison of treatment results. Int J Radiat Oncol Biol Phys. 1995;32:1425-1431.
30. Akine Y, Arimoto H, Ogino T, Kajiura Y, Tsukiyama I, Egawa S, et al. High dose rate intracavitary irradiation in the treatment of carcinoma of the uterine cervix: Early experience with 84 patients. Int J Radiat Oncol Biol Phys. 1988;17:893-898.
31. Arai T, Nakano T, Morita S, Sakashita K, Nakamura YK, Fukuhisa K. High dose rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. Cancer. 1992;69:175-180.
32. Ferrigno R, Nishimotot IN, Novaes PER, Pellizzon ACA, Maia MAC, Fogarolli RC, et al. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series. Int J Radiat Oncol Biol Phys. 2005;62:1108-1116.
33. Sakata KI, Nagakura H, Oouchi A, et al. High dose rate intracavitary brachytherapy: Results of analyses of late rectal complications. Int J Radiat Oncol Biol Phys. 2002;54:1369-1376.
34. Wong FCS, Tung SY, Leung TW, et al. Treatment results of high dose rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimes. Int J Radiat Oncol Biol Phys. 2003;55:1254-1264.
35. Lorvidhaya V, Tonusin A, Changwiwit W, et al. High dose rate afterloading brachytherapy in carcinoma of the cervix: An experience of 1992 patients. Int J Radiat Oncol Biol Phys. 2000;46:1185-1191.
36. Falkenberg E, Kim RY, Meleth S, De Los Santos J, Spencer S. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience. Brachytherapy. 2006;5:49-55.
37. Teshima T, Inoue T, Ikeda H, et al. High dose rate and low dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer. 1993;72:2409-2414.
38. Patel FD, Sharma SC, Negi PS, et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: A clinical trial. Int J Radiat Oncol Biol Phys. 1993;28:335-341.
39. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, Khorprasert C, Rojpornpradit P, Chottetanaprasith T, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1424-1431.
40. Hareyama M, Sakata K, Oouchi A, et al. High dose rate versus low dose rate intracavitary therapy for carcinoma of the uterine cervix. Cancer. 2002;94:117-124.
41. Souhami L, Corns R, Duclos M, Portelance L, Bahoric B, Stanimir G. Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. Gyn Oncol. 2005;97:508-513.
42. Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV Radiother Oncol. 2005;74:235-245.
43. Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC ESTRO Working Group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67-77.
44. Kirisits C, Potter R, Lang S, Dimopoulos J, Wachter-Gerstner N, Georg D. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005;62:901-911.
45. Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J, Pickel H, Lahousen M, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;42:531-540.
46. Aristizabal SA, Surwit EA, Hevezi JM, Heusinkveld RS. Treatment of advanced cancer of the cervix with transperineal interstitial irradiation. Int J Radiat Oncol Biol Phys. 1983;9:1013-1017.
47. Hughes-Davies L, Silver B, Kapp D. Parametrial interstitial brachytherapy for advanced or recurrent pelvic malignancy: The Harvard/Stanford experience. Gynecol Oncol. 1995;58:24-27.
48. Fontanesi J, Dylewski G, Photopulos G, Tai DL, Eddy T, Kun LE. Impact of dose on local control and development of complications in patients with advanced gynecological malignancies treated by interstitial template boost technique. Endocuriether Hyperther Oncol. 1993;9:115-119.
49. Syed AMN, Puthawala AA, Abdelaziz NN, et al. Long term results of low dose rate interstitial intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002;54:67-78.
50. Demanes DJ, Rodriguez RR, Bendre DD, et al. High dose rate transperineal interstitial brachytherapy for cervical cancer: High pelvic control and low complication rates. Int J Radiat Oncol Biol Phys. 1999;45:105-112.
51. Kirisits C, Lang S, Dimopoulos J, Berger D, Georg D, Potter R. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Desgin, application, treatment planning and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;65:624-630.
52. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972.
53. Souhami L, Seymour R, Roman TN, et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1993;27:871-878.
54. Strauss HG, Kuhnt T, Laban C, et al. Chemoradiation in cervical cancer with cisplatin and high dose rate brachytherapy combined with external beam radiotherapy. Results of a phase II study. Strahlenther Onkol. 2002;178:378-385.
55. Ozsaran Z, Yalman D, Yurut V, Aras A, Ozsaran A, Hanhan M, et al. Radiochemotherapy for patients with locally advanced cervical cancer. Early results. Eur J Gynaecol Oncol. 2003;24:191-194.
56. Sood BM, Gorla GR, Garg M, et al. Extended field radiotherapy and high dose rate brachytherapy in carcinoma of the uterine cervix: Clinical experience with and without concomitant chemotherapy. Cancer. 2003;9:1791-1798.
57. Sood BM, Gorla G, Gupta S, et al. Two fractions of high dose rate brachytherapy in the management of cervix cancer: Clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:702-706.
58. Saibishkumar EP, Patel FD, Sharma SC. Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: An experience from India. Bull Cancer. 2005;92:E7-E12.
59. Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, et al. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Gynecol Oncol. 1997;66:52-58.
60. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis. Clin Oncol. 2002;14:203-212.